Ensitrelvir Effectively Prevents Spread of COVID-19 in Households
By Lori Solomon HealthDay Reporter
THURSDAY, March 20, 2025 -- For household contacts of individuals with COVID-19, taking ensitrelvir within 72 hours of symptoms is effective at preventing infection and generally well tolerated, according to a study presented at the annual Conference on Retroviruses and Opportunistic Infections, held from March 9 to 12 in San Francisco.
Akimasa Fukushi, M.D., of Shionogi & Co., Ltd, in Osaka, Japan, and colleagues randomly assigned household contacts (HHC) of index patients (IP) with COVID-19 to receive either ensitrelvir (1,030 participants; day 1: 375 mg; day 2 to 5: 125 mg) or placebo (1,011 participants) within 72 hours of symptom onset in the IP.
The researchers found that the overall proportion of HHC developing confirmed COVID-19 was significantly lower in the ensitrelvir group (2.9 percent) versus the placebo group (9.0 percent; risk ratio [RR], 0.33) for HHC with central laboratory-confirmed SARS-CoV-2 negativity by reverse transcription polymerase chain reaction (RT-PCR). For HHC regardless of central laboratory RT-PCR results at baseline, similar results were seen (RR, 0.43). Across both groups, the proportions developing treatment-emergent adverse events (TEAEs; 15.1 percent for ensitrelvir and 15.5 percent for placebo) or serious TEAEs (0.2 versus 0.2 percent) were similar, as were the TEAEs seen in >1.5 percent of patients in either group: headache (2.9 versus 2.5 percent), diarrhea (1.8 versus 1.3 percent), and influenza (1.1 versus 1.6 percent). No COVID-19-related hospitalizations or fatalities were seen.
"In addition to vaccination, postexposure prophylaxis with timely use of an oral antiviral would be a valuable way to help prevent COVID-19 illness in people who have been exposed, especially people at high risk for severe disease," presenting author Frederick G. Hayden, M.D., from the University of Virginia in Charlottesville, said in a statement.
The study was funded by Shionogi & Co., Ltd, the manufacturer of ensitrelvir.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted March 2025
Further Support and Information on COVID-19
Read this next
Widespread Decline Seen in MMR Vaccination Rates After COVID-19
THURSDAY, June 5, 2025 -- A widespread decrease in measles-mumps-rubella (MMR) vaccination rates was seen after the COVID-19 pandemic, according to a research letter published...
Total Number of Excess Deaths >14.7 Million in U.S. in 1980 to 2023
THURSDAY, May 29, 2025 -- There were 14,735,913 excess deaths in the United States during 1980 to 2023 compared with other high-income countries (HICs), according to a research...
Medicaid Unwinding Linked to Disruption of Chronic Medication Therapy in Youth
FRIDAY, May 16, 2025 -- In young patients, especially young adults, Medicaid unwinding associated with the COVID-19 pandemic disrupted chronic medication therapy, according to a...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.